-

CEO, Jakob Lindberg will present at BIO Europe Spring in Stockholm April 3-6

Encouraging phase II data in multiple myeloma was presented at ASH annual meeting in December 2015, the poster can be downloaded here.

Oncopeptides is planning a pivotal phase III superiority study in late-stage multiple myeloma. The program includes 2 additional phase II studies and 1 additional phase I/II study. For further information or to arrange a meeting for discussions please contact Jakob Lindberg (CEO) or Björn Hammarberg (BD).

Upcoming events

Silent Period

-

FDA - Oncologic Drugs Advisory Committee (ODAC) Meeting

The US Food and Drug Administration, FDA, has announced a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (ODAC), on October 28, 2021 concerning Oncopeptides’ product Pepaxto. The information is in line with the FDA safety alert on July 28, where the FDA stated that a public meeting may be hold to discuss the safety findings from the OCEAN study.

Interim Report Q3 2021

08:00 CET

Silent Period

-

Year-end report 2021

08:00 CET

Silent Period

-

Silent Period

-